コンテンツへスキップ
Merck

55514

Sigma-Aldrich

BioStab Antibody Stabilizer

別名:

Antibody Stabilizer BioStab

ログイン組織・契約価格を表示する


About This Item

UNSPSCコード:
12352204
NACRES:
NA.25

テクニック

HPLC: suitable

品質水準

不純物

DNases, none detected
RNases, none detected
phosphatases, none detected
proteases, none detected

適合性

corresponds for identity (HPLC)

保管温度

2-8°C

アプリケーション

Antibodies can be protected from degradation effects using BioStab Antibody Stabilizer. The addition of BioStab Antibody Stabilizer increases life-time and the coating rates of the antibodies. BioStab Antibody Stabilizer can be used in ELISA, Western Blotting, Immunohistochemistry and any other applications which require marker or biotinylated antibodies. This stabilizer contains a minimum amount of a surfactant.

保管分類コード

11 - Combustible Solids

WGK

WGK 3

引火点(°F)

Not applicable

引火点(℃)

Not applicable

個人用保護具 (PPE)

Eyeshields, Gloves, type N95 (US)


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

55514-250ML-F:
55514-1L-F:
55514-250ML-BULK-F:
55514-1L-BULK-F:


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Jarem Edwards et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 25(11), 3247-3258 (2019-02-20)
Immunotherapies targeting costimulating and coinhibitory checkpoint receptors beyond PD-1 and CTLA-4 have entered clinical trials. Little is known about the relative abundance, coexpression, and immune cells enriched for each specific drug target, limiting understanding of the biological basis of potential
Lakshman N Subbaraman et al.
Optometry and vision science : official publication of the American Academy of Optometry, 82(3), 209-214 (2005-03-16)
Lysozyme deposits extracted from lotrafilcon silicone hydrogel (SH) contact lens materials demonstrate a loss in total mass as a function of storage time when assessed by Western blotting. This loss represents a potential source of error when quantifying total lysozyme
Eduardo P Melo et al.
Current protein & peptide science, 11(8), 744-751 (2011-01-18)
Biomedical applications of osmolytes, including stabilization of protein-based pharmaceutics, preservation of living biological material and potential therapeutic prescription in vivo, are intimately related to the fact that osmolytes favour the native structure of proteins. The shift towards the native structure
E Ron et al.
Journal of immunological methods, 180(2), 237-245 (1995-03-27)
A two step simple procedure for antibody stabilization in soluble form was developed. The antibody is first treated with low molecular weight polyaldehyde (polyglutaraldehyde). Following removal of non-bound polyaldehyde the antibody-polyaldehyde conjugate is crosslinked by polyamine (alkyl amine derivative of
Tim Serno et al.
Advanced drug delivery reviews, 63(13), 1086-1106 (2011-09-13)
Aggregation is arguably the biggest challenge for the development of stable formulations and robust manufacturing processes of therapeutic proteins. In search of novel excipients inhibiting protein aggregation, cyclodextrins and their derivatives have been under examination for use in parenteral protein

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)